The possibility of having incontinence as a side effect from all of the primary prostate cancer treatments is significant. Incontinence is not an either or thing as the degree of incontinence varies from individual to individual. Those men having significant levels of inconvenience find that their quality of life is significantly damaged in some cases [...]
The cost of Enzalutamide (Xtandi) in the United States is being challenged by Knowledge Ecology International (KEI), a public interest advocacy group. The average US wholesale price of Xtandi in 2015 was $88 per capsule. That can add up to $129,000 annual cost per man. There are significant issues related to high costs of treatment. [...]
Nizoral (ketoconazole, keto) is an older drug that has been used as a part of hormone therapy (ADT) for many years. Keto, which is an inexpensive anti-fungal drug had been used for many years as an inhibitor of adrenal androgen synthesis as is abiriterone (Zytiga). Ztiga has been shown to be more effective, however, it [...]
We are seeing more and more novel therapies being developed to treat castrate resistant metastatic prostate cancer (mCRPC). One such therapy involves theranostic (individualized therapies for various diseases, and to combine diagnostic and therapeutic capabilities into a single agent) concepts using radiolabeled ligands of the prostate-specific membrane antigen (PSMA). In a recent study, designed to [...]
Increasingly, we are seeing younger men diagnosed with prostate cancer and with bone metastases. One of the more common therapies, radiotherapy is recognized for its effect on local control of bone metastases, but whether it could prolong overall survival, the gold standard is still controversial. Researchers retrospectively evaluated 113 men with prostate cancer and bone [...]